PGI16 COST-EFFECTIVENESS OF ON-TREATMENT MONITORING OF HBSAG LEVELS TO PREDICT RESPONSE TO PEGINTERFERON-ALPHA-2A FOR HEPATITIS B TREATMENT UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL